Edition:
India

BioLife Solutions Inc (BLFS.OQ)

BLFS.OQ on NASDAQ Stock Exchange Capital Market

7.20USD
8:43pm IST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$7.20
Open
$7.24
Day's High
$7.24
Day's Low
$7.19
Volume
4,623
Avg. Vol
19,808
52-wk High
$7.83
52-wk Low
$2.01

Chart for

About

BioLife Solutions, Inc. (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management... (more)

Overall

Beta: 0.29
Market Cap(Mil.): $100.01
Shares Outstanding(Mil.): 14.15
Dividend: --
Yield (%): --

Financials

  BLFS.OQ Industry Sector
P/E (TTM): -- 29.67 32.21
EPS (TTM): -0.21 -- --
ROI: -28.87 13.44 13.05
ROE: -41.14 15.16 14.90

BRIEF-Casdin Capital To Become Shareholder In Biolife Solutions

* CASDIN CAPITAL LLC, ENTERED INTO AN AGREEMENT TO PURCHASE 1,000,000 BIOLIFE SOLUTIONS SHARES IN PRIVATE DEAL Source text for Eikon: Further company coverage:

09 Apr 2018

BRIEF-BioLife Solutions Announces Preliminary Q1 Revenue Of $3.8 Mln, Up 61 Pct

* FOR 2018 BIOPRESERVATION MEDIA REVENUE EXPECTED TO RANGE BETWEEN $14.5 MILLION TO $15.5 MILLION

02 Apr 2018

BRIEF-BioLife Solutions Q4 Loss Per Share $0.05

* BIOLIFE SOLUTIONS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

09 Mar 2018

BRIEF-Biolife Solutions Executes OEM Agreement With MilliporeSigma

* BIOLIFE SOLUTIONS EXECUTES OEM AGREEMENT WITH MILLIPORESIGMA Source text for Eikon: Further company coverage:

13 Feb 2018

BRIEF-Biolife Solutions Says Co And Savsu Technologies Amended Their Arrangement With Respect To JV

* BIOLIFE SOLUTIONS SAYS ON JAN 22 CO AND SAVSU TECHNOLOGIES AMENDED THEIR ARRANGEMENT WITH RESPECT TO THEIR JV, BIOLOGISTEX- SEC FILING

27 Jan 2018

BRIEF-Biolife Solutions Executes Supply Agreement With Iovance Biotherapeutics

* BIOLIFE SOLUTIONS EXECUTES SUPPLY AGREEMENT WITH IOVANCE BIOTHERAPEUTICS

13 Dec 2017

BRIEF-Biolife Solutions Executes Additional Long-Term Supply Agreement With Leading T Cell Therapy Customer

* BIOLIFE SOLUTIONS EXECUTES ADDITIONAL LONG-TERM SUPPLY AGREEMENT WITH LEADING T CELL THERAPY CUSTOMER Source text for Eikon: Further company coverage:

29 Nov 2017

BRIEF-BioLife Solutions posts Q3 loss per share $0.03

* Biolife Solutions announces third quarter 2017 financial results

10 Nov 2017

BRIEF-Biolife Solutions to report Q3 results and provide business update on Nov 9

* Biolife Solutions to report third quarter 2017 financial results and provide business update on November 9, 2017 Source text for Eikon: Further company coverage:

02 Nov 2017

Competitors

Earnings vs. Estimates